TONIX PHARMACEUTICALS HOLDING CORP. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $11.49 million as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-12
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $11.49M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $9.17M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $10.28M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $7.35M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $11.49M 10-K · filed 2026-03-12 | |
| 2024-12-31 | $9.17M 10-K · filed 2026-03-12 | |
| 2023-12-31 | $10.28M 10-K · filed 2025-03-18 | |
| 2022-12-31 | $7.35M 10-K · filed 2024-04-01 | |
| 2021-12-31 | $5.83M 10-K · filed 2023-03-13 | |
| 2020-12-31 | $3.66M 10-K · filed 2022-03-14 | |
| 2019-12-31 | $2.95M 10-K · filed 2021-03-15 | |
| 2018-12-31 | $2.66M 10-K · filed 2020-03-24 | |
| 2017-12-31 | $2.42M 10-K · filed 2019-03-18 | |
| 2016-12-31 | $4.38M 10-K · filed 2018-03-09 | |
| 2015-12-31 | $3.19M 10-K · filed 2017-04-13 | |
| 2014-12-31 | $1.34M 10-K · filed 2016-03-03 | $1.34M 10-K · filed 2015-02-27 |
| 2013-12-31 | $0.00 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |